TICKERNERD
Menu
PNTGPNTGHealthcare · Medical Care Facilities

PNTG Stock Forecast: The Pennant Group, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$39
−0.31% on the day

The 7 Wall Street analysts covering The Pennant Group, Inc. hold a median 12-month price target of $47 — +19.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.4B
Ticker Nerd rank
72 / 100
Median analyst target
$47
Analysts covering
7
Total return, dividends reinvested
1W
−1.1%
1M
−6.2%
YTD
+38.1%
1Y
+57.1%
From 52W high
−7.5%
From 52W low
+64.5%
$24
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PNTG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores The Pennant Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
92
Momentum
91
Growth
79
Volatility
69
Quality
62
Value
50
Size
42
Accruals
27
Issuance
18

Revisions (92): Analysts have, on balance, been raising their forecasts.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PNTG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PNTG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$25$30$35$40$45$50Oct 25Jan 26Apr 26Jul 26PNTGHigh $49Median $47Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $44Median $47High $49

The green dot is the last close — the median target sits +19.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
20 Aug 2026RBC CapitalMaintainsOutperform$42 → $44
11 Aug 2026Wells FargoMaintainsOverweight$45 → $46
14 July 2026Truist SecuritiesMaintainsBuy$42 → $48
14 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026Wells FargoMaintainsOverweight$41 → $45
13 July 2026Wells FargoMaintainsOverweight—
8 May 2026RBC CapitalMaintainsOutperform—
8 May 2026Truist SecuritiesMaintainsBuy—
8 May 2026Wells FargoMaintainsOverweight—
13 Apr 2026Truist SecuritiesMaintainsBuy—
2 Mar 2026RBC CapitalMaintainsOutperform—
7 Jan 2026Wells FargoMaintainsOverweight—
8 Dec 2025William BlairInitiatesOutperform—
2 Dec 2025Truist SecuritiesUpgradeBuy—
18 Nov 2025Wells FargoUpgradeOverweight—
17 Nov 2025RBC CapitalMaintainsOutperform—
24 Oct 2025JefferiesInitiatesBuy—
9 Oct 2025Stephens & Co.ReiteratesOverweight—
4 Sept 2025Stephens & Co.ReiteratesOverweight—
14 Aug 2025Wells FargoMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PNTG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PNTG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.0%
Analysts raising
5
Analysts cutting
0
Fundamentals

The Pennant Group, Inc. (PNTG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
42.7×

Cheaper than 18% of US stocks

Price / sales
1.2×

Cheaper than 65% of US stocks

Price / book
3.8×

Cheaper than 28% of US stocks

EV / EBITDA
25.3×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
35.8%

Higher than 81% of US stocks

Earnings growth (YoY)
28.2%

Higher than 65% of US stocks

Gross margin
14.1%

Higher than 14% of US stocks

Operating margin
6.2%

Higher than 57% of US stocks

Net margin
2.9%

Higher than 55% of US stocks

Returns & dividend
Return on equity
10.4%

Higher than 64% of US stocks

Return on assets
4.5%

Higher than 73% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PNTG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
PNTGThe Pennant Group, Inc.$1.4B
72
AMNAMN Healthcare Services, Inc.$1.3B
100
NUTXNutex Health, Inc.$1.3B
88
INNVInnovAge Holding Corp.$1.5B
96
USPHU.S. Physical Therapy, Inc.$1.2B
51
ARDTArdent Health, Inc.$1.6B
56
AGLAgilon Health, Inc.$1.6B
63

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own The Pennant Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PNTG news & analysis

OPCH vs. PNTG: Which Stock Is the Better Value Option?

Zacks Investment Research · 7 Aug 2026neutral

Zacks Investment Research published an article comparing Option Care (OPCH) and The Pennant Group, Inc. (PNTG) from a value-investing perspective, posing which of the two stocks offers a better value option for investors in the Medical - Outpatient and Home Healthcare sector.

Why it matters — PNTG watchers would be interested in how their stock is positioned relative to a peer in value terms, which could factor into investment considerations.

The Pennant Group Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

The Pennant Group reported second-quarter 2026 revenue and adjusted earnings growth across its home health, hospice, and senior living segments, leading the company to raise its full-year outlook.

Why it matters — A raised full-year outlook signals that the company's operating momentum across all three business lines is tracking ahead of its own expectations, which is a key data point for PNTG shareholders.

The Pennant Group, Inc. (PNTG) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of The Pennant Group, Inc.'s (PNTG) Q2 2026 earnings call, covering the company's management discussion of its quarterly results.

Why it matters — A PNTG watcher would review the transcript for management's commentary on the company's quarterly performance and guidance.

The Pennant Group, Inc. (PNTG) Tops Q2 Earnings and Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

The Pennant Group, Inc. reported second-quarter earnings of $0.36 per share, exceeding the Zacks Consensus Estimate of $0.33 per share. This compares with earnings of $0.27 per share in the same quarter a year ago.

Why it matters — A PNTG watcher would care because the company surpassed consensus earnings expectations and improved its results compared with the prior-year quarter.

Pennant Reports Second Quarter 2026 Results

GlobeNewsWire · 5 Aug 2026neutral

The Pennant Group, Inc. announced its operating results for the second quarter of 2026, reporting GAAP diluted earnings per share of $0.25 and adjusted diluted earnings per share of $0.36 for the quarter.

Why it matters — The announcement provides PNTG watchers with the company's latest quarterly earnings figures for home health, hospice and senior living operations.

FAQ

Frequently asked questions about PNTG stock

What is the PNTG stock price forecast for 2026-2027?

The 7 Wall Street analysts covering The Pennant Group, Inc. have a median 12-month price target of $47, with estimates ranging from $44 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PNTG stock a buy right now?

Of the 7 analysts covering The Pennant Group, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Pennant Group, Inc. 72 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PNTG?

As at 22 Aug 2026, The Pennant Group, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).

Will PNTG stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +19.6% from the last close, and Ticker Nerd's factor model ranks The Pennant Group, Inc. 72 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PNTG stock forecast for 2030?

No analyst covering The Pennant Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PNTG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $49 over the next 12 months.

How has PNTG stock performed over the past year?

The Pennant Group, Inc. returned +57.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does The Pennant Group, Inc. do?

Pennant Group, Inc. is a publicly traded healthcare company engaged in providing a range of post-acute healthcare services throughout the United States.

What is the latest news on PNTG?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "OPCH vs. PNTG: Which Stock Is the Better Value Option?". Zacks Investment Research published an article comparing Option Care (OPCH) and The Pennant Group, Inc. (PNTG) from a value-investing perspective, posing which of the two stocks offers a better value option for investors in the Medical - Outpatient and Home Healthcare sector.

Company

About The Pennant Group, Inc.

Pennant Group, Inc. is a publicly traded healthcare company engaged in providing a range of post-acute healthcare services throughout the United States. Its primary function is to operate home health and hospice agencies, as well as senior living communities, dedicated to offering skilled nursing and housing services to elderly populations. The company particularly serves the needs of individuals requiring specialized care following hospitalizations or those managing chronic health conditions, thereby playing a significant role in the continuum of care for aging demographics. Notably, Pennant Group, Inc. impacts the healthcare and real estate sectors, given its combined focus on healthcare services and residential community management. It stands out for its decentralized service model designed to empower local leadership and maximize community engagement, thereby tailoring services to the specific needs of each location. In the financial market, Pennant Group, Inc. represents a blend of healthcare provision with an emphasis on home-based care solutions, reflecting broader industry trends towards personalized and localized healthcare delivery systems. As the demand for senior care services continues to rise amidst an aging population, the company holds an important place in addressing these evolving healthcare needs.

CEO Mr. Brent J. Guerisoli · 7,000 employees · United States · https://pennantgroup.com